In this regards, EGFRvIII is particularly interesting as the deletion in the extracellular domain creates a tumor‐specific epitope that can be used as a target for anti‐EGFR antibodies for targeting the fastest proliferating cells. This evidence concerns the gene EGFR and neoplasm.